iwCLL 2019 | FCR treatment eligibility

Florence Cymbalista

Florence Cymbalista, MD, PhD, Avicenne Hospital, Bobigny, France, speaks on patient eligibility for fludarabine cyclophosphamide rituximab (FCR) treatment and the hurdles that must be overcome in order to better tailor treatment to individuals. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video